Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors
Ijin Joo, Jung Hoon Kim, Jeong Min Lee, Jin Woo Choi, Joon Koo Han, Byung Ihn Choi
Ultrasonography. 2014;33(1):18-25. Published online 2013 Nov 15 DOI: https://doi.org/10.14366/usg.13006
Citations to this article as recorded by 
Early response evaluation of doxorubicin-nanoparticle-microbubble therapy in orthotopic hepatocellular carcinoma rat model using contrast-enhanced ultrasound and intravoxel incoherent motion-diffusion MRI
Hyun Kyung Yang, Jung Hoon Kim, Hak Jong Lee, Hyungwon Moon, Hwaseong Ryu, Joon Koo Han
Ultrasonography.2022; 41(1): 150. CrossRef
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
Hyehyun Jeong, Yong Sang Hong, Jeong Eun Kim, Hyeong-Seok Lim, Joong Bae Ahn, Sang Joon Shin, Young Suk Park, Seung Tae Kim, Sae-Won Han, Tae-You Kim, Tae Won Kim
Investigational New Drugs.2021; 39(5): 1335. CrossRef
Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer
Soo Jin Kim, Kyung Hwan Jegal, Ji-Hye Im, Gyutae Park, Suntae Kim, Hye Gwang Jeong, Il Je Cho, Keon Wook Kang
Cancer Chemotherapy and Pharmacology.2020; 85(4): 685. CrossRef
Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study
In Joon Lee, Myungsu Lee, Soo Jin Kim, You Kyung Kim, Jong Yun Won, Jin Wook Chung
Journal of Vascular and Interventional Radiology.2018; 29(8): 1078. CrossRef
Enhanced efficacy of radiofrequency ablation for hepatocellular carcinoma using a novel vascular disrupting agent, CKD-516
Su Jung Ham, YoonSeok Choi, Seul-I Lee, Jinil Kim, Young Il Kim, Jin Wook Chung, Kyung Won Kim
Hepatology International.2017; 11(5): 446. CrossRef
Comparison of tumor vascularity and hemodynamics in three rat hepatoma models
Jin Woo Choi, Jung Hoon Kim, Hyo-Cheol Kim, Won Seok Choi, Song Yi Baek, Kyoungbun Lee, Jin Wook Chung
Abdominal Radiology.2016; 41(2): 257. CrossRef
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
Do-Youn Oh, Tae-Min Kim, Sae-Won Han, Dong-Yeop Shin, Yun Gyoo Lee, Keun-Wook Lee, Jee Hyun Kim, Tae-You Kim, In-Jin Jang, Jong-Seok Lee, Yung-Jue Bang
Cancer Research and Treatment.2016; 48(1): 28. CrossRef
Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model
Hee Sun Park, Joon Koo Han, Jeong Min Lee, Young Il Kim, Sungmin Woo, Jung Hwan Yoon, Jin-Young Choi, Byung Ihn Choi
Korean Journal of Radiology.2015; 16(5): 1029. CrossRef
Feasibility of Using Volumetric Contrast-Enhanced Ultrasound with a 3-D Transducer to Evaluate Therapeutic Response after Targeted Therapy in Rabbit Hepatic VX2 Carcinoma
Jeehyun Kim, Jung Hoon Kim, Soon Ho Yoon, Won Seok Choi, Young Jae Kim, Joon Koo Han, Byung-Ihn Choi
Ultrasound in Medicine & Biology.2015; 41(12): 3131. CrossRef